MENLO PARK, Calif. and SINGAPORE, Nov. 10, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in-person at the 12
th
Annual Jefferies London Healthcare Conference on November 17, 2021, at 1:00pm GMT. The conference will be held in-person November 16 and 17, 2021 and virtually November 18 and 19, 2021.
A live webcast of the discussion can be accessed using this link:
https://wsw.com/webcast/jeff201/asln/1840068
with a replay available shortly afterwards in the News & Events section of ASLAN’s Investor Relations website at
https://ir.aslanpharma.com/
Media and IR contacts
|
Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: [email protected] |
Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: [email protected] |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit
www.aslanpharma.com
or follow ASLAN on
LinkedIn
.
